[Federal Register Volume 83, Number 210 (Tuesday, October 30, 2018)]
[Notices]
[Pages 54604-54605]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-23616]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is jointly owned by an agency of 
the U.S. Government with Pontificia Universidad Catolica de Chile and 
is available for licensing to achieve expeditious commercialization of 
results of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent application listed below may be obtained by 
communicating with Ami Gadhia, JD, LL.M., CLP, Technology Transfer and 
Patenting Specialist, National Center for Advancing Translational 
Sciences, NIH, 9800 Medical Center Drive, Rockville, MD 20850, Phone: 
301-217-6098, or email [email protected]. A signed Confidential 
Disclosure Agreement will be required to receive copies of unpublished 
patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
c-Abl Tyrosine Kinase Inhibitory Compounds and Methods of Manufacture 
and Use

Description of Technology

    The invention includes compounds that inhibit c-Abl tyrosine 
kinase, and methods of making them which include administering (i) a 
therapeutically effective amount of the compound or a stereoisomer, 
tautomer, pharmaceutically acceptable salt, solvate, or prodrug 
thereof; or (ii) a therapeutically effective amount of the 
pharmaceutical compositions to a patient with the disease which 
involves c-Abl tyrosine kinase, including the overexpression of it. In 
some embodiments, the compound inhibits c-Abl tyrosine kinase by 
binding to an allosteric site of the c-Abl tyrosine kinase. In some 
embodiments, the compound binds to a myristate pocket of the c-Abl 
tyrosine kinase.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further

[[Page 54605]]

development and evaluation under a research collaboration.

Potential Commercial Applications

     Novel therapeutics for neurodegenerative diseases AND 
other indications which involve c-Abl kinase (e.g., lysosomal storage 
disorders, cancers, etc.).

Competitive Advantages

     Novel compounds that have a commercial advantage over 
those currently known because they are able to selectively bind to c-
Abl at an allosteric site, can cross the blood-brain barrier, and show 
robust efficacy in several neurodegenerative models. All of this allows 
them to potentially treat neurodegenerative diseases, cancer etc.

Development Stage

     Pre-Clinical (in vivo validation).

Inventors

     Juan Marugan, Marc Ferrer, Noel Southall, Andres Dulcey, 
Xin Hu, Christopher Dextras, Daniel Talley, Alejandra Alvarez, Silvana 
Zanlungo.
    Intellectual Property: 1. C-ABL TYROSINE KINASE INHIBITORY COMPOUND 
EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME'' U.S. Provisional 
Patent Application NO. 62/641,126 filed on March 9, 2018 (HHS Ref. No. 
E-252-2017).
    Licensing Contact: Ami Gadhia, JD, LL.M., CLP, 301-217-6098; 
[email protected].

    Dated: September 25, 2018.
Lillianne M. Portilla Weingarten,
Technology Development Coordinator, National Center for Advancing 
Translational Sciences.
[FR Doc. 2018-23616 Filed 10-29-18; 8:45 am]
BILLING CODE 4140-01-P